Buserelin as primary therapy in advanced prostatic carcinoma.

Area of Science:

• Oncology
• Endocrinology

Background:

• Advanced prostate cancer (Stages C/D) requires effective treatment options.
• Luteinizing hormone-releasing hormone (LHRH) agonists are used in prostate cancer therapy.

Purpose of the Study:

• To evaluate the effectiveness of buserelin in patients with advanced prostate cancer.
• To assess treatment response, duration, and impact on patient-reported outcomes.

Main Methods:

• A study involving 28 patients with Stages C or D adenocarcinoma of the prostate.
• Buserelin treatment was administered, and outcomes were assessed using National Prostatic Cancer Project criteria.

Main Results:

• 54% of evaluable patients achieved partial responses, with a median duration over 6 months.
• 38% had stable disease (median duration >5 months), and only 2 progressed.
• Significant improvements were observed in performance status (38%), pain (46%), and quality of life (57%).

Conclusions:

• Buserelin is an effective treatment for advanced prostate cancer, inducing frequent and meaningful remissions.
• The treatment demonstrated positive effects on patient-reported symptoms and quality of life.
• Common side effects included hot flashes, loss of libido, and impotence, with minimal symptom flare observed.